Sanofi successfully prices €1.5 billion bond issue

 

Sanofi successfully prices €1.5 billion bond issue

Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches: 

• €750 million fixed-rate notes, due June 2029, bearing interest at an annual rate of 2.625%.
• €750 million fixed-rate notes, due June 2032, bearing interest at an annual rate of 3.000%.

The notes are being issued off the company's Euro Medium Term Note Programme.

Sanofi intends to use the net proceeds of the offering for general corporate purposes.

The transaction has been led by Citigroup and RBC Capital Markets as Global Coordinators, and Credit Agricole CIB, HSBC and Societe Generale, all as Joint Lead Managers.

About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations 
Sandrine Guendoul | + 33 6 25 09 14 25 | [e-mail]
Evan Berland | [phone] | [e-mail]
Victor Rouault | + 33 6 70 93 71 40 | [e-mail]
Léo Le Bourhis | + 33 6 75 06 43 81 | [e-mail]
Timothy Gilbert | + 1 516 521 2929 | [e-mail]
Léa Ubaldi | [phone] | [e-mail] 

Investor Relations 
Thomas Kudsk Larsen | + 44 7545 513 693 | [e-mail]
Alizé Kaisserian | + 33 6 47 04 12 11 | [e-mail]
Felix Lauscher | + 1 908 612 7239 | [e-mail]
Keita Browne | + 1 781 249 1766 | [e-mail]
Nathalie Pham | + 33 7 85 93 30 17 | [e-mail]
Tarik Elgoutni | + 1 617 710 3587 | [e-mail]
Thibaud Châtelet | + 33 6 80 80 89 90 | [e-mail]
Yun Li | [phone] | [e-mail]

Disclaimer 
This communication shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This is neither an advertisement and not a prospectus for the purposes of Regulation (EU) 2017/1129 of June 14, 2017 (as amended, the “Prospectus Regulation”), nor a prospectus within the meaning of Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 (the “UK Prospectus Regulation”), and has not been approved, filed or reviewed by any regulatory authority of the EEA or the United Kingdom.